Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
Iodide uptake across the membranes of thyroid follicular cells and cancer cells occurs through an active transport process mediated by the sodium-iodide symporter (NIS). The rat and human NIS-coding genes were cloned and identified in 1996. Evaluation of NIS gene and protein expression is critical f...
Main Authors: | June-Key Chung, Gi Jeong Cheon |
---|---|
Format: | Article |
Language: | English |
Published: |
Academya Publishing Co.
2014-09-01
|
Series: | Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-29-233.pdf |
Similar Items
-
Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer
by: Yoon Ju Choi, et al.
Published: (2021-01-01) -
Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer
by: Lin Liu, et al.
Published: (2017-09-01) -
Progress in gene therapy for prostate cancer
by: Kamran Ali Ahmed, et al.
Published: (2012-11-01) -
Cancer gene therapy: Prospects of using human sodium iodide symporter gene in non-thyroidal cancer
by: Shruti Dutta, et al.
Published: (2015-01-01) -
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
by: Jierui Liu, et al.
Published: (2019-09-01)